anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Current retrospective observational study aims to assess the reliability and validity of gait pattern classification systems in ambulatory children with CP. Gait classification is often performed using kinematic gait data obtained via a three dimensional (3D) data captured in a specialized gait lab using infra-red cameras. However, not all hospitals and clinical centers have access to such a specialized gait lab, and therefore often use video recordings as an alternative for gait classification. It is currently not known whether such a classification based on solely video recordings is equally reliable in comparison with kinematic gait data. For this purpose, current study aims to assess the reliability and validity of video recordings to classify children with CP according to predefined gait classifications. Sagittal plane video recordings during barefoot walking in children with CP will be used to classify the study participants into seven different gait classification patterns. For reliability, inter-rater reliability between raters scoring the video recordings will be assessed. To evaluate whether video recordings could serve as a valid alternative for kinematic gait data, the agreement between the classifications from the video recordings and the kinematic data additionally will be assessed.
Patients receive sintilimab IV on day 1, etoposide IV on days 1-3 of courses 1-6, carboplatin IV on day 2 of courses 1-6, and ifosfamide IV on day 1-3 of courses 1-6. Sintilimab in combination with ICE chemotherapy repeats every 21 days for 6 courses.
In a method for measuring healthcare quality, a plurality of computers operating in parallel receive from a patient dataset representative of patients within a healthcare organization, the patient dataset being distributed across the plurality of computer as subsets of patient datasets. The plurality of computers receive at least one healthcare quality measure definition comprising a numerator and a denominator. The plurality of computers identify, in the subsets of patient datasets, patient data that corresponds to the measure definition. The plurality of computers attribute the identified patient data to at least one provider based on an attribution rule. The plurality of computers calculate at least one healthcare quality measure for the at least one provider, according to the healthcare quality measure definition, based on the attributed patient encounters. The plurality of computers store the at least one calculated healthcare quality measure in a measure dataset.
Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
The present invention relates to a method for the complexation of erythrocruorin from E. Fetida on the external surfaces of liposomes to improve the surface area of ??the liposomal structure and preserve the bioavailability and functionality of the protein used in oxygen transport within biological systems. Said complex has the desired physicochemical characteristics, such as stability and appropriate size of up to 250 nm, avoiding extravasation and secondary effects in the kidney. Also, it includes photoluminescent properties that help location without modifying the protein. Additionally, it possesses the advantage of achieving the complexation of erythrocruorin, with or without PEG, on the external surface of the liposomes, allowing the complexing of various molecules because the erythrocruorin protein is smaller than the average6 diameter thereof. Further, liposomes function as oxygen-rich carriers, making said nanoplatforms in biological systems attractive.
Clobetasol propionate was not carcinogenic to rats when topically applied for 2 years at concentrations up to 0.005% which corresponded to doses up to 11 μg/kg/day (ratio of animal dose to proposed human dose of 0.03 on a mg/m2/day basis).

Clobetasol propionate at concentrations up to 0.001% did not increase the rate of formation of ultra violet light-induced skin tumors when topically applied to hairless mice 5 days per week for a period of 40 weeks.

Clobetasol propionate was negative in the in vitro mammalian chromosomal aberration test and in the in vivo mammalian erythrocyte micronucleus test.

The effect of subcutaneously administered clobetasol propionate on fertility and general reproductive toxicity was studied in rats at doses of 0, 12.5, 25, and 50 μg/kg/day. Males were treated beginning 70 days before mating and females beginning 15 days before mating through day 7 of gestation. A dosage level of less than 12.5 μg/kg/day clobetasol propionate was considered to be the no-observed-effect-level (NOEL) for paternal and maternal general toxicity based on decreased weight gain and for male reproductive toxicity based on increased weights of the seminal vesicles. The female reproductive NOEL was 12.5 μg/kg/day (ratio of animal dose to proposed human dose of 0.03 on a mg/m2/day basis) based on reduction in the numbers of estrous cycles during the pre-cohabitation period and an increase in the number of nonviable embryos at higher doses.
The invention discloses a Parabacteroides strain, a culture method and application thereof. The Parabacteroides strain is Parabacteroides strain F1-28( Parabacteroides sp.F1-28), the bacterial strain is separated from human excrement, the bacterial strain is preserved in China center for type culture Collection, and the preservation number is CCTCC NO: m2022645. The invention discloses the application of the strain in preparing medicamentApplication in treating inflammatory bowel disease and application in preparing health food. The strain can degrade the algin and the derivatives thereof, and the strain can grow better in a culture medium which takes the algin with the molecular weight of 100kDa as a unique carbon source. The strain has good therapeutic effect on Inflammatory Bowel Disease (IBD) induced by Dextran Sodium Sulfate (DSS). In a mouse model of inflammatory bowel disease induced by dextran sodium sulfate, the strain can slow down the weight reduction of mice, increase the colorectal length and relieve the phenomena of stool dilution and hematochezia of the mice caused by the inflammatory bowel disease. The strain can reduce histology and inflammation score of mice with inflammatory bowel diseases, and has good effect of treating inflammatory bowel diseases.
The flooding of agricultural land leads to hypoxia and nitrate leaching. While understanding the plant's response to these conditions is essential for crop improvement, the effect of extended nitrate limitation on subsequent hypoxia has not been studied in an organ-specific manner. We cultivated Arabidopsis thaliana without nitrate for 1 week before inducing hypoxia by bubbling the hydroponic solution with nitrogen gas for 16 h. In the roots, the transcripts of two transcription factor genes (HRA1, HRE2) and three genes involved in fermentation (SUS4, PDC1, ADH1) were ~10- to 100-fold upregulated by simultaneous hypoxia and nitrate starvation compared to the control condition (replete nitrate and oxygen). In contrast, this hypoxic upregulation was ~5 to 10 times stronger when nitrate was available. The phytoglobin genes PGB1 and PGB2, involved in nitric oxide (NO) scavenging, were massively downregulated by nitrate starvation (~1000-fold and 105-fold, respectively), but only under ambient oxygen levels; this was reflected in a 2.5-fold increase in NO concentration. In the leaves, HRA1, SUS4, and RAP2.3 were upregulated ~20-fold by hypoxia under nitrate starvation, whereas this upregulation was virtually absent in the presence of nitrate. Our results highlight that the plant's responses to nitrate starvation and hypoxia can influence each other.
Patients undergo observation following standard of care surgery. Patients undergo modified barium swallow study (MBSS) at pre-op, 2 weeks post-op, and 3 months follow-up. Patients also undergo CT, PET/CT, or magnetic MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing at pre-op, 1-2 days post-op, 2 weeks post-op, and 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months as well as saliva sample collection at pre-op, end of RT, and any clinical recurrence.
Methods and systems for determining drug trend and drug inflation are described. In one embodiment, an index sample may be selected including an identification of a plurality of drugs. A weighting factor associated with each of the plurality of drugs in the index sample may be calculated. A first weighted price of for the plurality of drugs may be calculated for a first time period. A second weighted price for the plurality of drugs may be calculated for a second time period. A price index may be calculated for the second time period based on the first weighted price and the second weighted price. Other methods and systems are described.
The invention relates to the technical field of bioengineering, and provides a complex enzyme for hydrolyzing eggshell membrane, which comprises keratinase and alkaline protease in a mass ratio of 0.2-5: 1. The complex enzyme can make the eggshell membrane hydrolyzed more fully. The hydrolysis method of the eggshell membrane comprises the following steps: mixing the eggshell membrane dry powder with water, preserving heat for 10-240 minutes at 70-80 ℃, cooling to 50-55 ℃, and preserving heat to obtain an eggshell membrane liquid; adjusting the pH value of the eggshell membrane liquid to 8.0-8.5, adding a complex enzyme, and continuously preserving the temperature to obtain an eggshell membrane hydrolysis mixed liquid. The hydrolysis method can make eggshell membrane hydrolyzed sufficiently. The method for extracting the eggshell membrane hydrolysate comprises the method for hydrolyzing the eggshell membrane, adjusting the pH to 5.0-8.0, heating to 90-100 ℃, preserving the heat for 10-60 minutes, filtering, concentrating and spray drying. The hydrolysate obtained by the extraction method has high yield and good quality. The invention also provides the eggshell membrane hydrolysate prepared by the extraction method.
1385272 Osmotic-pressure-activated dispenser ALZA CORP 12 Jan 1972 [13 Jan 1971 (2)] 1553/72 Heading B1X [Also in Divisions A5 and F1] Material to be dispensed is contained in an impervious bag having outlet means, the bag being subjected either directly or indirectly to pressure generated by infiltration of water into a solution exhibiting an osmotic pressure gradient against water. In the embodiment shown in Fig. 1 the bag 14 is enclosed with a further bag 16 permeable to water and containing the solution, in an outer perforated housing 12. In other embodiments the material bag is in the solution which is contained in an outer housing which is either permeable to water or has a membrane permeable to water, the housing being perforated to allow water to have access to the membrane (Figs. 3-8 not shown). An embodiment (Fig. 9 not shown) is described which is manufactured from a plastics tube. Suitable materials for the container components are mentioned and also suitable salts for the solution. Devices according to the invention in which the impervious bag is filled with a drug may be implanted in a living body and are operated by body fluid entering the osmotic solution e.g. an intravaginal device (Fig. 2 not shown), device administered via the gastrointestinal track, device retained in the rumen of an animal, bolus, I.O.D., vaginal ring, uterine capsule, artificial gland, pusthesis, pissary, suppository and the like. The device may be finally soluble. Other uses are discharging pesticides into water and a catalyst into an aqueous reaction medium. An integral water supply container may be provided.
Oxidative stress has been identified as a major factor in the development and progression of pain and psychiatric disorders, but the underlying biomarkers and molecular signaling pathways remain unclear. This study aims to identify oxidative stress-related biomarkers and signaling pathways in pain-depression comorbidity. Integrated bioinformatics analyses were applied to identify key genes by comparing pain-depression comorbidity-related genes and oxidative stress-related genes. A total of 580 differentially expressed genes and 35 differentially expressed oxidative stress-related genes (DEOSGs) were identified. By using a weighted gene co-expression network analysis and a protein-protein interaction network, 43 key genes and 5 hub genes were screened out, respectively. DEOSGs were enriched in biological processes and signaling pathways related to oxidative stress and inflammation. The five hub genes, RNF24, MGAM, FOS, and TKT, were deemed potential diagnostic and prognostic markers for patients with pain-depression comorbidity. These genes may serve as valuable targets for further research and may aid in the development of early diagnosis, prevention strategies, and pharmacotherapy tools for this particular patient population.
NEW MATERIAL:A compound shown by formula I [A is carbonyl or sulfonyl; B is group shown by formula II - formula IV (R1 and R2 are H or one of R1 and R2 is H and the other is OH, alkyl, etc.; E is methylene, O, etc.; broken line part shows single bond or double bond; R is methylene or ethylene; R3-R8 are H or alkyl; R9 and R10 are lower alkyl; R11 and R12 are lower alkyl, etc.; n is 0-2) when A is carbonyl and B is 1,2-phenylene when A is sulfonyl; W is lower alkylene, lower alkenylene; G is substituted benzoisothiazolyl, (substituted)benzoyl, etc.]. EXAMPLE:A compound shown by formula VII. USE:An antipsychotic agent having extremely weak side effects of extrapyramidal motor system and strong effects even by oral administration. PREPARATION:For example, a compound shown by formula VIII (X is eliminable group) is reacted with a compound shown by formula IX in a solvent such as acetonitrile, etc., in the presence of an acid binder such as potassium carbonate, etc., at room temperature - under heating.
PROBLEM TO BE SOLVED: To obtain the subject new compound capable of improving insulin resistance which is a cause of hyperlipemia and non-insulin dependent diabetes mellitus, having high safety and useful as an effective hypoglycemic agent. SOLUTION: This is a compound expressed by formula I [(n) is 2 or 3], e.g. 5-(2-formylethenyl)-2-methoxy benzoic acid methyl. A compound of formula I is produced by reacting a compound of formula II with a compound of formula III. The reaction is carried out in an organic solvent, e.g. dimethylsulfoxide using a condensing agent, e.g. 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide and optionally adding an organic base (e.g. triethylamine). The reaction temperature ranges from ice cooling to room temperature.
BACKGROUND: Rare diseases are generally poorly understood from scientific and medical standpoints due, to their complexity and low prevalence. As a result, individuals living with rare diseases struggle to obtain timely diagnoses and suitable care. These clinical difficulties add to the physical and psychological impacts of living with chronic and often severe medical conditions. From the standpoint of pragmatist ethics, the morally problematic situations that adults living with rare diseases experience matter crucially. However, there is little known about these experiences.
METHODS: A survey study was conducted with 121 adults living with rare diseases in Québec, Canada, to identify morally problematic situations encountered in the healthcare system and everyday life as part of a participatory action research project. Morally problematic situations elicited internal tensions and constraints to agency.
RESULTS: Adults living with rare diseases experienced morally problematic situations of stigmatization, disbelief, and sometimes abuse in the healthcare system. These situations were compounded by diagnostic delays, inadequate care, and suboptimal follow-up, and led some individuals to opt-out of medical care. In their personal lives, these individuals sometimes found themselves in situations of physical and financial dependency. They often also had to give up professional occupations, academic training, or life projects.
CONCLUSIONS: Adults living with rare diseases experience important morally problematic situations navigating the healthcare system and their everyday lives, some of which could be alleviated through interventions developed through future participatory action research.
Rare cases of death or hospitalization due to severe liver injury have been reported post-marketing in association with the use of bicalutamide. Hepatotoxicity in these reports generally occurred within the first three to four months of treatment. Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in approximately 1% of bicalutamide patients in controlled clinical trials. 

Serum transaminase levels should be measured prior to starting treatment with bicalutamide, at regular intervals for the first four months of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (e.g., nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, or right upper quadrant tenderness), the serum transaminases, in particular the serum ALT, should be measured immediately. If at any time a patient has jaundice, or their ALT rises above two times the upper limit of normal, Bicalutamide Tablets should be immediately discontinued with close follow-up of liver function.
Patients receive irinotecan hydrochloride IV over 90 minutes followed 5 hours later by leucovorin calcium IV over 2 hours and alvocidib IV over 1 hour immediately followed by 5-FU IV continuously over 48 hours beginning on day 1 of weeks 1, 3, and 5. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of alvocidib and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients are treated at the MTD.
OBJECTIVE: To investigate the altered trends of regional homogeneity (ReHo) based on time and frequency, and clarify the time-frequency characteristics of ReHo in 48 classical trigeminal neuralgia (CTN) patients after a single pain stimulate.
METHODS: All patients underwent three times resting-state functional MRI (before stimulation (baseline), after stimulation within 5 s (triggering-5 s), and in the 30th min of stimulation (triggering-30 min)). The spontaneous brain activity was investigated by static ReHo (sReHo) in five different frequency bands and dynamic ReHo (dReHo) methods.
RESULTS: In the five frequency bands, the number of brain regions which the sReHo value changed in classical frequency band were most, followed by slow 4 frequency band. The left superior occipital gyrus was only found in slow 2 frequency band and the left superior parietal gyrus was only found in slow 3 frequency band. The dReHo values were changed in midbrain, left thalamus, right putamen, and anterior cingulate cortex, which were all different from the brain regions that the sReHo value altered. There were four altered trends of the sReHo and dReHo, which dominated by decreased at triggering-5 s and increased at triggering-30 min.
CONCLUSIONS: The duration of brain function changed was more than 30 min after a single pain stimulate, although the pain of CTN was transient. The localized functional homogeneity has time-frequency characteristic in CTN patients after a single pain stimulate, and the changed brain regions of the sReHo in five frequency bands and dReHo complemented to each other. Which provided a certain theoretical basis for exploring the pathophysiology of CTN.
This study aims to demonstrate the feasibility of using a new wireless electroencephalography (EEG)-electromyography (EMG) wearable approach to generate characteristic EEG-EMG mixed patterns with mouth movements in order to detect distinct movement patterns for severe speech impairments. This paper describes a method for detecting mouth movement based on a new signal processing technology suitable for sensor integration and machine learning applications. This paper examines the relationship between the mouth motion and the brainwave in an effort to develop nonverbal interfacing for people who have lost the ability to communicate, such as people with paralysis. A set of experiments were conducted to assess the efficacy of the proposed method for feature selection. It was determined that the classification of mouth movements was meaningful. EEG-EMG signals were also collected during silent mouthing of phonemes. A few-shot neural network was trained to classify the phonemes from the EEG-EMG signals, yielding classification accuracy of 95%. This technique in data collection and processing bioelectrical signals for phoneme recognition proves a promising avenue for future communication aids.
An artificial intelligence (AI)-assisted evaluation method for aesthetic medicine and an evaluation system are provided. An AI aesthetic medicine identification and analysis module is used. An AI facial expression evaluation module provides a real-time facial expression evaluation result of a subject. The real-time facial expression evaluation result is inputted into the AI aesthetic medicine identification and analysis module. The AI aesthetic medicine identification and analysis module optionally cooperates with at least one of a medical knowledge rule module and an aesthetic medicine auxiliary evaluation result historical database to perform an AI aesthetic medicine identification and analysis process. Then, the AI aesthetic medicine identification and analysis module generates and outputs a real-time aesthetic medicine auxiliary evaluation result. According to the real-time aesthetic medicine auxiliary evaluation result, an aesthetic medicine behavior is carried out. Consequently, the personalized aesthetic therapeutic effect can be achieved.
Foetal anomalies as detected on prenatal ultrasound are present in 2-3% of pregnancies. The diagnosis of a genetic syndrome as the underlying cause often has significant consequences for the prognosis and therefore also a significant impact on parental reproductive decision making. In addition to chromosomal testing, prenatal exome sequencing (pES) is increasingly being offered. Although prenatal diagnostic rates are promising, no studies report on the actual implementation of pES in routine care and thus several important knowledge gaps remain regarding clinical utility (the balance between potential harms and benefits) and the preferred analysis strategy (broad versus targeted analysis). A broad analysis has a possible higher diagnostic yield, but it is unknown whether the increased chance of finding an uncertain diagnosis and Incidental Findings outweighs this benefit when it comes to clinical decision making and parental psychological wellbeing. The central aim of this study is to address the knowledge gaps raised above, and increase clinical utility by using the obtained data to improve analysis strategies and to potentially identify new genes.